And, as they generate sales of BRANDED prodicts, it will show up in the chart over the summer.
As the others out there find that they are not able to generate products that have the necessary pharmaceutical consistency at competative prices, it will eventually become a fact that MJNA's competition will have to buy ingredients from them.
It is worth it to have less flash and more substance, IMHO.
And what's better: being the company slogging through the headwinds of a bureaucratic nightmare, year after year, or being the company whose low cost, consistent pharmaceutical ingredients are required by ANY company in this niche who hopes to eventually release a drug?
Imperial Whazoo
Market Data 
Markets 
AI
